论文部分内容阅读
目的研究依泽麦布辛伐他汀与不同剂量的辛伐他汀用于PCI患者二级预防中的疗效和安全性.方法 选取在湖北省阳新县人民医院经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的患者共448例,随机分为A组(148例,给予依泽麦布辛伐他汀10 mg/20 mg)、B组(150例,给予辛伐他汀40 mg);C组(150例,给予辛伐他汀20 mg).对出院患者进行定期随访,评估其降脂疗效、安全性和主要不良心血管事件(MACE)发生率.结果治疗后,A组和B组的血脂达标率和低密度脂蛋白胆固醇(LDL-C)含量显著低于C组(P<0.05),A组肝功能异常的比例显著低于B组(P<0.05),A组MACE发生率低于其他两组(P<0.05).患者PCI术后血脂不达标、血压不达标、血糖不达标、未服用依泽麦布辛伐他汀与MACE发生独立相关.结论 依泽麦布辛伐他汀用于PCI患者的二级预防能显著降低血脂,安全性高,减少MACE的发生.“,”Objective To study the Efficacy and safety of Ezetimibe/simvastatin and different doses of Simvastatin Tablets in secondary prevention in Percutaneous coronary intervention patients. Methods Selected 448 cases of patients with coronary interventional therapy in our hospital,randomly divided them into A group(148 cases),treated with Ezetimibe/simvastatin tablets(10mg/20mg);group B(150 cases),treated with Simvastatin Tablets 40mg;group C (150 cases),treated with the Simvastatin Tablets 20mg.All patients were taking the medicine once a day before going to bed. Regular follow-up was performed to assess the efficacy, safety and major adverse cardiac event. Results (1) group A and group B were significantly higher than the group C in blood lipid compliance rate,range of low densith lipoprotein were significantly lower after treatment,group A with liver dysfunction was significantly lower than group B, The incidence of MACE in group A was lower than that in the other two groups(p<0.05).(2)No standards of blood fat、blood pressure、blood glucose and no taken of Ezetimibe/simvastatin were independently associated with major adverse cardiac event. Conclusion The application of Ezetimibe/simvastatin in secondary prevention of PCI patients significantly lower blood lipid,high safety,reduced the incidence of major adverse cardiovascular events.